International Journal of
Reproductive Biomedicine
Thu, Nov 21, 2024
[Archive]
Volume 18, Issue 7 (July 2020)
IJRM 2020, 18(7): 531-538 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kohestani Y, Kohestani B, Shirmohamadi Z, Faghani M. Effect of tamsulosin on testis histopathology and serum hormones in adult rats: Experimental study. IJRM 2020; 18 (7) :531-538
URL: http://ijrm.ir/article-1-1320-en.html
URL: http://ijrm.ir/article-1-1320-en.html
1- Department of Anatomical Sciences, Bandar-Anzali Pardis, Faculty of Medicine, Guilan University of Medical Sciences, Bandar-Anzali, Iran.
2- Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Department of Biostatistics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4- Department of Anatomical Sciences, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran. ,mfaghani2000@gmail.com
2- Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Department of Biostatistics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4- Department of Anatomical Sciences, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran. ,
Abstract: (2154 Views)
Background: Tamsulosin is an inhibitory factor of alpha-adrenergic receptors that is used for relieving of the clinical symptoms and management of acute urinary retention.
Objective: The aim of this study was to evaluate the effects of tamsulosin on the endocrine axis and testicular tissue in adult male rats.
Materials and Methods: In this experimental study, 30 adult male Wistar rats (weighing 250-300 gr) were divided into three groups: 1) control (received distilled water), 2) experimental 1 (received 0.2 mg/kg/day tamsulosin) and 3) experimental 2 (received 0.4 mg/kg/day tamsulosin) through oral gavage for 28 days. Serum hormones level and testicular histopathology were evaluated at the end of the experiment.
Results: In this study, the testicular weight decreased significantly in the experimental groups compared to the control group. A significant decrease was seen in testicular weight (p = 0.004) and the number of Leydig cells in tamsulosin-treated groups (p = 0.012). Tamsulosin improved the hormone profile in experimental groups. Also, higher dose of tamsulosin significantly changed the number of Leydig, spermatogonia cells, the thickness of germinal layer, and the diameter of the seminiferous tubules.
Conclusion: Results showed that using tamsulosin, possibly reduces the testosterone concentration through adrenergic axis system and in turn has destructive effects on proliferative activity of germ cells.
Objective: The aim of this study was to evaluate the effects of tamsulosin on the endocrine axis and testicular tissue in adult male rats.
Materials and Methods: In this experimental study, 30 adult male Wistar rats (weighing 250-300 gr) were divided into three groups: 1) control (received distilled water), 2) experimental 1 (received 0.2 mg/kg/day tamsulosin) and 3) experimental 2 (received 0.4 mg/kg/day tamsulosin) through oral gavage for 28 days. Serum hormones level and testicular histopathology were evaluated at the end of the experiment.
Results: In this study, the testicular weight decreased significantly in the experimental groups compared to the control group. A significant decrease was seen in testicular weight (p = 0.004) and the number of Leydig cells in tamsulosin-treated groups (p = 0.012). Tamsulosin improved the hormone profile in experimental groups. Also, higher dose of tamsulosin significantly changed the number of Leydig, spermatogonia cells, the thickness of germinal layer, and the diameter of the seminiferous tubules.
Conclusion: Results showed that using tamsulosin, possibly reduces the testosterone concentration through adrenergic axis system and in turn has destructive effects on proliferative activity of germ cells.
Type of Study: Original Article |
Subject:
Reproductive Biology
References
1. Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017; 4: 148-151. [DOI:10.1016/j.ajur.2017.06.004] [PMID] [PMCID]
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479. [DOI:10.1016/S0022-5347(17)49698-4]
3. Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JR. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J Urol 2009; 181: 710-716. [DOI:10.1016/j.juro.2008.10.025] [PMID]
4. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990; 17: 241-246. [DOI:10.1002/pros.2990170308] [PMID]
5. Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 2006; 68: 804-809. [DOI:10.1016/j.urology.2006.04.019] [PMID]
6. Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population‐based Krimpen‐study: Prediction of future prostate volume in individual men. Prostate 2007; 67: 1816-1824. [DOI:10.1002/pros.20663] [PMID]
7. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol 2009; 182: 1458-1462. [DOI:10.1016/j.juro.2009.06.047] [PMID] [PMCID]
8. Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol 2008; 53: 819-825. [DOI:10.1016/j.eururo.2007.08.042] [PMID]
9. Konstantinidis C, Samarinas M, Andreadakis S, Xanthis S, Skriapas K. Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin-a prospective study. Urol Int 2013; 90: 156-160. [DOI:10.1159/000345050] [PMID]
10. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol 2003; 5: 72-80.
11. Dunn CJ, Matheson A, Faulds DM. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002; 19: 135-161. [DOI:10.2165/00002512-200219020-00004] [PMID]
12. Insel PA. Structure and function of alpha-adrenergic receptors. Am J Med 1989; 87: S12-S18. [DOI:10.1016/0002-9343(89)90108-3]
13. Kim JJ, Han DH, Sung HH, Choo SH, Lee SW. Efficacy and tolerability of tamsulosin 0.4 mg in A sian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: a randomized placebo controlled trial. Int J Urol 2014; 21: 677-682. [DOI:10.1111/iju.12412] [PMID]
14. Rowe PJ, Comhaire FH, Hargreave TB, Mahmoud AM. WHO manual for the standardized investigation and diagnosis of the infertile male. Cambridge University Press: UK; 2000.
15. Dohle GR, Colpi GM, Hargreave TB, Papp GK, Jungwirth A, Weidner W, et al. EAU guidelines on male infertility. Eur Urol 2005; 48: 703-711. [DOI:10.1016/j.eururo.2005.06.002] [PMID]
16. Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. BMC Urol 2019; 19: 17-28. [DOI:10.1186/s12894-019-0446-8] [PMID] [PMCID]
17. Pogula VR, Kadiyala LS, Gouru VR, Challa SR, Byram R, Bodduluri S. Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study. Cent Eur J Urol 2019; 72: 44-50.
18. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892-900. [DOI:10.1016/S0090-4295(98)00126-5]
19. Arruzazabala ML, Mas R, Molina V, Noa M, Carbajal D, Mendoza N. Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phenylephrine in rats. Drugs R D 2006; 7: 233-241. [DOI:10.2165/00126839-200607040-00003] [PMID]
20. Goktas S, Kibar Y, Kilic S, Topac H, Coban H, Seckin B. Recovery of abnormal ejaculation by intermittent tamsulosin treatment. J Urol 2006; 175: 650-653. [DOI:10.1016/S0022-5347(05)00157-6]
21. Kamimura H, Oishi S, Matsushima H, Watanabe T, Higuchi S, Hall M, et al. Identification of cytochrome P450 isozymes involved in metabolism of the α 1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998; 28: 909-922. [DOI:10.1080/004982598238985] [PMID]
22. Ratnasooriya WD, Wadsworth RM. Tamsulosin, a selective alpha 1‐adrenoceptor antagonist, inhibits fertility of male rats. Andrologia 1994; 26: 107-110. [DOI:10.1111/j.1439-0272.1994.tb00766.x] [PMID]
23. Selvage DJ, Lee SY, Parsons LH, Seo DO, Rivier CL. A hypothalamic-testicular neural pathway is influenced by brain catecholamines, but not testicular blood flow. Endocrinology 2004; 145: 1750-1759. [DOI:10.1210/en.2003-1441] [PMID]
24. Lee S, Miselis R, Rivier C. Anatomical and functional evidence for a neural hypothalamic-testicular pathway that is independent of the pituitary. Endocrinology 2002; 143: 4447-4454. [DOI:10.1210/en.2002-220392] [PMID]
25. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13. [DOI:10.1159/000019919] [PMID]
26. Yang PS, Chen CL, Hou CP, Lin YH, Tsui KH. An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin. Clin Interv Aging 2018; 13: 235-242. [DOI:10.2147/CIA.S152701] [PMID] [PMCID]
27. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. lancet Oncol 2009; 10: 981-991. [DOI:10.1016/S1470-2045(09)70229-3]
28. Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, et al. Efficacy and safety of a fixed‐dose combination of dutasteride and tamsulosin treatment (D uodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment‐naïve men with moderately symptomatic benign prostatic hyperplasia: 2‐year CONDUCT study results. BJU Int 2015; 116: 450-459. [DOI:10.1111/bju.13033] [PMID]
29. Beltagy D, Ali H, Abdel-Gelil A, Abdel-Gawad A, Abdel Aziz K. Impact of Finasteride and Tamsulosin Hydrochloride Administration on sex hormones, prostatic markers and neurotransmitters in male rats. 2015. Available at: https://apps.who.int/iris/handle/10665/42437.
30. Ghadian A, Rezaei M. Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Inflammopharmacology 2017; 25: 451-458. [DOI:10.1007/s10787-017-0343-2] [PMID]
31. Choi BR, Kim HK, Soni KK, Karna KK, Lee SW, So I, et al. Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model. Drug Des Devel Ther 2018; 12: 1855-1863. [DOI:10.2147/DDDT.S164049] [PMID] [PMCID]
32. Alwachi SN, Husain DK. Research article Tamsulosin hydrochloride (flomax) effects on fertility of albino male mice. Int J Recent Sci Res 2014; 5: 326-331.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
